Live Breaking News & Updates on ரிக்கார்டோ மரேக்

Stay updated with breaking news from ரிக்கார்டோ மரேக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Takeda's Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1


Takeda Pharmaceutical Company Limited
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Friday, March 12, 2021 11:40AM IST (6:10AM GMT)
 
Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030
Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets
Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth
 
(TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targ ....

United Arab Emirates , United States , Buenos Aires , Distrito Federal , Holly Campbell , Kazumi Kobayashi , Ricardo Marek , Asia Pacific , Exchange Commission , Takeda Pharmaceutical Company Limited , Takeda Pharmaceutical Company , Digit Revenue Growth Expected , Focused Geographic Presence , Patient Access , Addressing Unmet Patient Needs , Emerging Markets Underpin Sustainable , Pharmaceutical Company Limited , Emerging Markets Business Unit , Emerging Markets , Costa Saroukos , Rare Genetic , Plasma Derived Therapies , Emerging Markets Business , South America , Middle East , Annual Report ,

Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index


Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
Wednesday, January 27, 2021 11:40AM IST (6:10AM GMT)
 
Company Ranked Sixth Overall and Leads the Pharmaceutical Industry in Governance of Access
Secured Industry-Leading Positions in All Three Technical Areas Evaluated
Shows Strong Performance in Health System Strengthening and Compliance
 
(TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021
Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index. ....

United States , United Kingdom , Christophe Weber , Kazumi Kobayashi , Ricardo Marek , Susanne Weissbaecker , Company Ranked Sixth Overall , Takeda Pharmaceutical Company Limited , Melinda Gates Foundation , Research Development , Takeda Pharmaceutical Company , Shows Strong Performance In Health System , Access To Medicine Foundation , Ranked Sixth Overall , Pharmaceutical Industry , Industry Leading Positions , All Three Technical Areas , Strong Performance , Health System Strengthening , Pharmaceutical Company Limited , Atm Index , Medicine Index , Emerging Markets Business Unit , Access First , Emerging Markets Region , Innovative Healthcare Access ,

Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index


Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
January 26, 2021 GMT
( TSE:4502/NYSE:TAK ) (“Takeda”) has earned an industry-leading position within the 2021
Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index.
ADVERTISEMENT
“This honor underscores Takeda’s commitment to prioritizing patient needs by ensuring access to our life-transforming treatments,” said Christophe Weber, Takeda president and chief executive officer. “As a purpose-driven company that puts the patient at the center of everything we do, we are committed ....

United States , United Kingdom , Christophe Weber , Holly Campbell , Kazumi Kobayashi , Ricardo Marek , Susanne Weissbaecker , Takeda Pharmaceutical Company Limited , Melinda Gates Foundation , Research Development , Access To Medicine Foundation , Takeda Pharmaceutical Company , Pharmaceutical Company Limited , Atm Index , Medicine Index , Emerging Markets Business Unit , Access First , Emerging Markets Region , Innovative Healthcare Access , Global Head , Medicines Initiatives , Patient Assistance Programs , Medicine Foundation , Technical Areas , Rare Genetic , Plasma Derived Therapies ,